Prognostic role of DOK family adapters in acute myeloid leukemia

[1]  J. Qian,et al.  Methylation‐associated DOK1 and DOK2 down‐regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia , 2018, Journal of cellular physiology.

[2]  J. Lionberger,et al.  Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk. , 2018, Leukemia research.

[3]  M. Gobbi,et al.  A blastic plasmacytoid dendritic cell neoplasm‐like phenotype identifies a subgroup of npm1‐mutated acute myeloid leukemia patients with worse prognosis , 2018, American journal of hematology.

[4]  Xiaojing Yan,et al.  Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia. , 2017, Biochemical and biophysical research communications.

[5]  K. Götze,et al.  Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. , 2017, European journal of cancer.

[6]  Suoni Li,et al.  Repression of DOK7 mediated by DNMT3A promotes the proliferation and invasion of KYSE410 and TE-12 ESCC cells. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  Lars Bullinger,et al.  Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Pandolfi,et al.  Dok1 and Dok2 Proteins Regulate Cell Cycle in Hematopoietic Stem and Progenitor Cells , 2016, The Journal of Immunology.

[9]  D. Birnbaum,et al.  Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML) , 2014, Leukemia.

[10]  P. Pandolfi,et al.  Dok1 and Dok2 proteins regulate natural killer cell development and function , 2014, The EMBO journal.

[11]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[12]  Hiroko Masuda,et al.  Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.

[13]  Erika Hooker,et al.  New insights into Dok-4 PTB domain structure and function. , 2012, Biochemical and biophysical research communications.

[14]  T. Spector,et al.  DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker , 2012, Carcinogenesis.

[15]  Guido Marcucci,et al.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[17]  M. Caligiuri,et al.  Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Haferlach,et al.  Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells , 2011, Haematologica.

[19]  I. Plaza-Menacho,et al.  RET in breast cancer: functional and therapeutic implications. , 2011, Trends in molecular medicine.

[20]  Seong-Jin Kim,et al.  TrkC plays an essential role in breast tumor growth and metastasis. , 2010, Carcinogenesis.

[21]  J. Dipersio,et al.  Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. , 2010, Blood.

[22]  H. Nakauchi,et al.  Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive histiocytic sarcoma , 2010, Laboratory Investigation.

[23]  Y. Yamanashi,et al.  The roles of Dok family adapters in immunoreceptor signaling , 2009, Immunological reviews.

[24]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[25]  B. Teh,et al.  DOK4/IRS‐5 expression is altered in clear cell renal cell carcinoma , 2007, International journal of cancer.

[26]  Xiaozhong Peng,et al.  Dok5 is substrate of TrkB and TrkC receptors and involved in neurotrophin induced MAPK activation. , 2006, Cellular signalling.

[27]  O. Acuto,et al.  T cell receptor for antigen induces linker for activation of T cell–dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2 , 2006, The Journal of experimental medicine.

[28]  P. Pandolfi,et al.  Downstream of Kinase, p62dok, Is a Mediator of FcγRIIB Inhibition of FcεRI Signaling1 , 2002, The Journal of Immunology.

[29]  W. Jiang,et al.  Evidence for Tumour Suppressor Function of DOK7 in Human Breast Cancer , 2014 .

[30]  E. Vellenga,et al.  Original Articles Design and Methods Prognostic Impact of White Blood Cell Count in Intermediate Risk Acute Myeloid Leukemia: Relevance of Mutated Npm1 and Flt3-itd , 2022 .